# EDGAR Filing Document

**Accession Number:** 0000009631
**File Stem:** 0001839882-25-031996
**Filing Date:** 2025-6
**Character Count:** 115366
**Document Hash:** 800aee9cdd06598cd3dc4d7773c7166f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001839882-25-031996.hdr.sgml**: 20250603

**ACCESSION NUMBER**: 0001839882-25-031996

**CONFORMED SUBMISSION TYPE**: 424B2

**PUBLIC DOCUMENT COUNT**: 13

**FILED AS OF DATE**: 20250603

**DATE AS OF CHANGE**: 20250603

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BANK OF NOVA SCOTIA
- **CENTRAL INDEX KEY:** 0000009631
- **STANDARD INDUSTRIAL CLASSIFICATION:** STATE COMMERCIAL BANKS [6022]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 134941099
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** 424B2
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-282565
- **FILM NUMBER:** 251017759

**BUSINESS ADDRESS:**
- **STREET 1:** 40 TEMPERANCE STREET
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5H 0B4
- **BUSINESS PHONE:** (416) 866-3672

**MAIL ADDRESS:**
- **STREET 1:** 40 TEMPERANCE STREET
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5H 0B4

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BANK OF NOVA SCOTIA /
- **DATE OF NAME CHANGE:** 19970702

---

| | |
|:---|:---|
| ![](image1.gif)  | **May 2025**<br> Pricing Supplement<br> Dated May 30, 2025<br> Registration Statement No. 333-282565<br> Filed pursuant to Rule 424(b)(2)<br> (To Prospectus dated November 8, 2024,<br> Prospectus Supplement dated November 8, 2024,<br> Underlier Supplement dated November 8, 2024<br> and Product Supplement dated November 8, 2024)<br>|

---

STRUCTURED INVESTMENTS

Opportunities in U.S. Equities

$3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031

The Partial Principal at Risk Securities (the "securities") will pay no interest and provide a minimum payment at maturity of only 95.00% of the stated principal amount. At maturity, if the final index value is greater than the initial index value, investors will receive the stated principal amount of their investment *plus* a return reflecting the upside performance of the underlying index, subject to the maximum payment at maturity. If the final index value is less than or equal to the initial index value, investors will lose 1% for every 1% that the final index value falls below the initial index value, subject to the minimum payment at maturity. **Accordingly, investors may lose up to 5% of the stated principal amount of the securities.** The securities are for investors who seek an index-based return and who are willing to risk 5% of their principal and forgo current income and upside above the maximum payment at maturity in exchange for the repayment of at least 95.00% of the stated principal amount if the final index value is less than or equal to the initial index value, subject to the credit risk of The Bank of Nova Scotia ("BNS"). The securities are senior unsecured debt securities issued by BNS. The securities are notes issued as part of BNS' Senior Note Program, Series A.

**All payments on the securities are subject to the credit risk of BNS. If BNS were to default on its payment obligations, you may not receive any amounts owed to you under the securities and you could lose your entire investment in the securities. These securities are not secured obligations and you will not have any security interest in, or otherwise have any access to, any underlying reference asset or assets.**

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp; SUMMARY TERMS | &nbsp;&nbsp; SUMMARY TERMS | &nbsp;&nbsp; SUMMARY TERMS | &nbsp;&nbsp; SUMMARY TERMS |
| &nbsp;&nbsp; **Issuer:** | &nbsp;&nbsp;&nbsp; The Bank of Nova Scotia ("BNS") | &nbsp;&nbsp;&nbsp; The Bank of Nova Scotia ("BNS") | &nbsp;&nbsp;&nbsp; The Bank of Nova Scotia ("BNS") |
| &nbsp;&nbsp; **Issue:** | &nbsp;&nbsp;&nbsp; Senior Note Program, Series A | &nbsp;&nbsp;&nbsp; Senior Note Program, Series A | &nbsp;&nbsp;&nbsp; Senior Note Program, Series A |
| &nbsp;&nbsp; **Underlying index:** | &nbsp;&nbsp;&nbsp; S&P 500<sup>®</sup> Index (Bloomberg Ticker: "SPX") | &nbsp;&nbsp;&nbsp; S&P 500<sup>®</sup> Index (Bloomberg Ticker: "SPX") | &nbsp;&nbsp;&nbsp; S&P 500<sup>®</sup> Index (Bloomberg Ticker: "SPX") |
| &nbsp;&nbsp; **Aggregate principal amount:** | &nbsp;&nbsp;&nbsp; $3145000 | &nbsp;&nbsp;&nbsp; $3145000 | &nbsp;&nbsp;&nbsp; $3145000 |
| &nbsp;&nbsp; **Stated principal amount:** | &nbsp;&nbsp;&nbsp; $1,000.00 per security | &nbsp;&nbsp;&nbsp; $1,000.00 per security | &nbsp;&nbsp;&nbsp; $1,000.00 per security |
| &nbsp;&nbsp; **Issue price:** | &nbsp;&nbsp;&nbsp; $1,000.00 per security (see "Commissions and issue price" below) | &nbsp;&nbsp;&nbsp; $1,000.00 per security (see "Commissions and issue price" below) | &nbsp;&nbsp;&nbsp; $1,000.00 per security (see "Commissions and issue price" below) |
| &nbsp;&nbsp; **Minimum investment:** | &nbsp;&nbsp;&nbsp; $1,000 (1 security) | &nbsp;&nbsp;&nbsp; $1,000 (1 security) | &nbsp;&nbsp;&nbsp; $1,000 (1 security) |
| &nbsp;&nbsp; **Coupon:** |  |  |  |
| &nbsp;&nbsp; **Pricing date:** | &nbsp;&nbsp;&nbsp; May 30, 2025 | &nbsp;&nbsp;&nbsp; May 30, 2025 | &nbsp;&nbsp;&nbsp; May 30, 2025 |
| &nbsp;&nbsp; **Original issue date:** | &nbsp;&nbsp;&nbsp; June 4, 2025 (3 business days after the pricing date). Under Rule 15c6-1 of the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day (T+1), unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade the securities in the secondary market on any date prior to one business day before delivery of the securities will be required, by virtue of the fact that the securities will settle in three business days (T+3), to specify alternative settlement arrangements to prevent a failed settlement of the secondary market trade. | &nbsp;&nbsp;&nbsp; June 4, 2025 (3 business days after the pricing date). Under Rule 15c6-1 of the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day (T+1), unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade the securities in the secondary market on any date prior to one business day before delivery of the securities will be required, by virtue of the fact that the securities will settle in three business days (T+3), to specify alternative settlement arrangements to prevent a failed settlement of the secondary market trade. | &nbsp;&nbsp;&nbsp; June 4, 2025 (3 business days after the pricing date). Under Rule 15c6-1 of the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day (T+1), unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade the securities in the secondary market on any date prior to one business day before delivery of the securities will be required, by virtue of the fact that the securities will settle in three business days (T+3), to specify alternative settlement arrangements to prevent a failed settlement of the secondary market trade. |
| &nbsp;&nbsp; **Valuation date:** | &nbsp;&nbsp;&nbsp; May 30, 2031, subject to postponement in the event of a market disruption event as described in the accompanying product supplement | &nbsp;&nbsp;&nbsp; May 30, 2031, subject to postponement in the event of a market disruption event as described in the accompanying product supplement | &nbsp;&nbsp;&nbsp; May 30, 2031, subject to postponement in the event of a market disruption event as described in the accompanying product supplement |
| &nbsp;&nbsp; **Maturity date:** | &nbsp;&nbsp;&nbsp; June 4, 2031, subject to postponement in the event of a market disruption event, as described in the accompanying product supplement | &nbsp;&nbsp;&nbsp; June 4, 2031, subject to postponement in the event of a market disruption event, as described in the accompanying product supplement | &nbsp;&nbsp;&nbsp; June 4, 2031, subject to postponement in the event of a market disruption event, as described in the accompanying product supplement |
| &nbsp;&nbsp; **Payment at maturity per security:** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ￭ If the final index value is **greater than** the initial index value:<br> *$1,000.00 + supplemental redemption amount, subject to the maximum payment at maturity*<br> ￭ If the final index value is **less than or equal to** the initial index value:<br> *$1,000.00 + ($1,000.00 × underlying return), subject to the minimum payment at maturity*<br> ***If the final index value is less than the initial index value, you will lose 1% for every 1% that the final index value falls below the initial index value, provided that the payment at maturity will not be less than the minimum payment at maturity. Accordingly, you could lose up to 5.00% of your investment in the securities. All payments on the securities are subject to the credit risk of BNS.*** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ￭ If the final index value is **greater than** the initial index value:<br> *$1,000.00 + supplemental redemption amount, subject to the maximum payment at maturity*<br> ￭ If the final index value is **less than or equal to** the initial index value:<br> *$1,000.00 + ($1,000.00 × underlying return), subject to the minimum payment at maturity*<br> ***If the final index value is less than the initial index value, you will lose 1% for every 1% that the final index value falls below the initial index value, provided that the payment at maturity will not be less than the minimum payment at maturity. Accordingly, you could lose up to 5.00% of your investment in the securities. All payments on the securities are subject to the credit risk of BNS.*** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ￭ If the final index value is **greater than** the initial index value:<br> *$1,000.00 + supplemental redemption amount, subject to the maximum payment at maturity*<br> ￭ If the final index value is **less than or equal to** the initial index value:<br> *$1,000.00 + ($1,000.00 × underlying return), subject to the minimum payment at maturity*<br> ***If the final index value is less than the initial index value, you will lose 1% for every 1% that the final index value falls below the initial index value, provided that the payment at maturity will not be less than the minimum payment at maturity. Accordingly, you could lose up to 5.00% of your investment in the securities. All payments on the securities are subject to the credit risk of BNS.*** |
| &nbsp;&nbsp; **Underlying return:** | &nbsp;&nbsp;&nbsp; (final index value - initial index value) / initial index value | &nbsp;&nbsp;&nbsp; (final index value - initial index value) / initial index value | &nbsp;&nbsp;&nbsp; (final index value - initial index value) / initial index value |
| &nbsp;&nbsp; **Supplemental redemption amount:** | &nbsp;&nbsp;&nbsp; $1,000.00 × underlying return | &nbsp;&nbsp;&nbsp; $1,000.00 × underlying return | &nbsp;&nbsp;&nbsp; $1,000.00 × underlying return |
| &nbsp;&nbsp; **Maximum gain:** | &nbsp;&nbsp;&nbsp; 70.58% | &nbsp;&nbsp;&nbsp; 70.58% | &nbsp;&nbsp;&nbsp; 70.58% |
| &nbsp;&nbsp; **Maximum payment at maturity:** | &nbsp;&nbsp;&nbsp; $1,705.80 per security (170.58% of the stated principal amount) | &nbsp;&nbsp;&nbsp; $1,705.80 per security (170.58% of the stated principal amount) | &nbsp;&nbsp;&nbsp; $1,705.80 per security (170.58% of the stated principal amount) |
| &nbsp;&nbsp; **Minimum payment at maturity:** | &nbsp;&nbsp;&nbsp; $950.00 per security (95.00% of the stated principal amount) | &nbsp;&nbsp;&nbsp; $950.00 per security (95.00% of the stated principal amount) | &nbsp;&nbsp;&nbsp; $950.00 per security (95.00% of the stated principal amount) |
| &nbsp;&nbsp; **Initial index value:** | &nbsp;&nbsp;&nbsp; 5,911.69, which is equal to the index closing value of the underlying index on the pricing date, as determined by the calculation agent and as may be adjusted as described under "General Terms of the Notes — Unavailability of the Closing Value of a Reference Asset; Adjustments to a Reference Asset — Unavailability of the Closing Value of a Reference Index; Alternative Calculation Methodology", as described in the accompanying product supplement | &nbsp;&nbsp;&nbsp; 5,911.69, which is equal to the index closing value of the underlying index on the pricing date, as determined by the calculation agent and as may be adjusted as described under "General Terms of the Notes — Unavailability of the Closing Value of a Reference Asset; Adjustments to a Reference Asset — Unavailability of the Closing Value of a Reference Index; Alternative Calculation Methodology", as described in the accompanying product supplement | &nbsp;&nbsp;&nbsp; 5,911.69, which is equal to the index closing value of the underlying index on the pricing date, as determined by the calculation agent and as may be adjusted as described under "General Terms of the Notes — Unavailability of the Closing Value of a Reference Asset; Adjustments to a Reference Asset — Unavailability of the Closing Value of a Reference Index; Alternative Calculation Methodology", as described in the accompanying product supplement |
| &nbsp;&nbsp; **Final index value:** | &nbsp;&nbsp;&nbsp; The index closing value of the underlying index on the valuation date, as determined by the calculation agent and as may be adjusted as described under "General Terms of the Notes — Unavailability of the Closing Value of a Reference Asset; Adjustments to a Reference Asset — Unavailability of the Closing Value of a Reference Index; Alternative Calculation Methodology", as described in the accompanying product supplement | &nbsp;&nbsp;&nbsp; The index closing value of the underlying index on the valuation date, as determined by the calculation agent and as may be adjusted as described under "General Terms of the Notes — Unavailability of the Closing Value of a Reference Asset; Adjustments to a Reference Asset — Unavailability of the Closing Value of a Reference Index; Alternative Calculation Methodology", as described in the accompanying product supplement | &nbsp;&nbsp;&nbsp; The index closing value of the underlying index on the valuation date, as determined by the calculation agent and as may be adjusted as described under "General Terms of the Notes — Unavailability of the Closing Value of a Reference Asset; Adjustments to a Reference Asset — Unavailability of the Closing Value of a Reference Index; Alternative Calculation Methodology", as described in the accompanying product supplement |
| &nbsp;&nbsp; **CUSIP/ISIN:** | &nbsp;&nbsp;&nbsp; 06418VA38 / US06418VA384 | &nbsp;&nbsp;&nbsp; 06418VA38 / US06418VA384 | &nbsp;&nbsp;&nbsp; 06418VA38 / US06418VA384 |
| &nbsp;&nbsp; **Listing:** | &nbsp;&nbsp;&nbsp; The securities will not be listed or displayed on any securities exchange or any electronic communications network | &nbsp;&nbsp;&nbsp; The securities will not be listed or displayed on any securities exchange or any electronic communications network | &nbsp;&nbsp;&nbsp; The securities will not be listed or displayed on any securities exchange or any electronic communications network |
| &nbsp;&nbsp; **Calculation agent:** | &nbsp;&nbsp;&nbsp; Scotia Capital Inc. | &nbsp;&nbsp;&nbsp; Scotia Capital Inc. | &nbsp;&nbsp;&nbsp; Scotia Capital Inc. |
| &nbsp;&nbsp; **Agent:** | &nbsp;&nbsp;&nbsp; Scotia Capital (USA) Inc. ("SCUSA"), an affiliate of BNS. See "Supplemental information regarding plan of distribution (conflicts of interest); secondary markets (if any)." | &nbsp;&nbsp;&nbsp; Scotia Capital (USA) Inc. ("SCUSA"), an affiliate of BNS. See "Supplemental information regarding plan of distribution (conflicts of interest); secondary markets (if any)." | &nbsp;&nbsp;&nbsp; Scotia Capital (USA) Inc. ("SCUSA"), an affiliate of BNS. See "Supplemental information regarding plan of distribution (conflicts of interest); secondary markets (if any)." |
| &nbsp;&nbsp; **Estimated value on the pricing date:** | &nbsp;&nbsp;&nbsp; $952.34 per stated principal amount, which is less than the issue price listed above. See "Additional Information About the Securities — Additional information regarding estimated value of the securities" herein and "Risk Factors — Risks Relating to Estimated Value and Liquidity" beginning on page 8 of this document for additional information. The actual value of your securities at any time will reflect many factors and cannot be predicted with accuracy. | &nbsp;&nbsp;&nbsp; $952.34 per stated principal amount, which is less than the issue price listed above. See "Additional Information About the Securities — Additional information regarding estimated value of the securities" herein and "Risk Factors — Risks Relating to Estimated Value and Liquidity" beginning on page 8 of this document for additional information. The actual value of your securities at any time will reflect many factors and cannot be predicted with accuracy. | &nbsp;&nbsp;&nbsp; $952.34 per stated principal amount, which is less than the issue price listed above. See "Additional Information About the Securities — Additional information regarding estimated value of the securities" herein and "Risk Factors — Risks Relating to Estimated Value and Liquidity" beginning on page 8 of this document for additional information. The actual value of your securities at any time will reflect many factors and cannot be predicted with accuracy. |
| &nbsp;&nbsp; **Commissions and issue price:** | &nbsp;&nbsp; **Price to Public**<sup>(1)</sup> | &nbsp;&nbsp; **Fees and Commissions**<sup>(1)</sup> | &nbsp;&nbsp; **Proceeds to Issuer** |
| &nbsp;&nbsp; **Per security:** | &nbsp;&nbsp;&nbsp; $1000.00 | &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$30.00<sup>(a)</sup> <br> <u>+</u> <u>$</u><u>5.00</u><sup>(b)</sup><br> $35.00 | &nbsp;&nbsp;&nbsp; $965.00 |
| &nbsp;&nbsp;&nbsp; **Total** **:** | &nbsp;&nbsp;&nbsp; $3145000.00 | &nbsp;&nbsp;&nbsp; $110075.00  | &nbsp;&nbsp;&nbsp; $3034925.00 |

---

*(1) SCUSA , has agreed to purchase the securities at the stated principal amount and, as part of the distribution of the securities, has agreed to sell all of the securities to Morgan Stanley Smith Barney LLC ("Morgan Stanley Wealth Management") at an underwriting discount which reflects:*

&nbsp;&nbsp;&nbsp;&nbsp;*(a) a* *fixed sales commission of $30.00 per $1,000.00 stated principal amount of the securities that Morgan Stanley Wealth Management sells and*

&nbsp;&nbsp;&nbsp;&nbsp;*(b) a fixed structuring fee of $5.00 per $1,000.00 stated principal amount of the securities that Morgan Stanley Wealth Management sells,* 

*each payable to Morgan Stanley Wealth Management. See "Additional Information About the Securities — Supplemental information regarding plan of distribution (conflicts of interest); secondary markets (if any)" herein.*

**The securities involve risks not associated with an investment in ordinary debt securities. See "Risk Factors" beginning on page 7.**

**Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this document, the accompanying product supplement, the underlier supplement, the prospectus supplement or the prospectus. Any representation to the contrary is a criminal offense.**

**The securities are not insured by the Canada Deposit Insurance Corporation (the "CDIC") pursuant to the Canada Deposit Insurance Corporation Act (the "CDIC Act") or the U.S. Federal Deposit Insurance Corporation or any other government agency of Canada, the U.S. or any other jurisdiction. The securities are not bail-inable debt securities under the CDIC Act.**

---

| | | | |
|:---|:---|:---|:---|
| [<u>Product supplement dated November 8, 2024</u>](http://www.sec.gov/Archives/edgar/data/9631/000183988224038316/bns_424b2-21309.htm) | [<u>Underlier supplement dated November 8, 2024</u>](http://www.sec.gov/Archives/edgar/data/9631/000183988224038308/bns_424b2-21314.htm) | [<u>Prospectus supplement dated November 8, 2024</u>](https://www.sec.gov/Archives/edgar/data/9631/000183988224038303/bns_424b3-21311.htm) | [<u>Prospectus dated November 8, 2024</u>](http://www.sec.gov/Archives/edgar/data/9631/000119312524253771/d875135d424b3.htm) |

---

------

---

| |
|:---|
| ![](image1.gif)  |
| $3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 |

---

Additional Information About BNS and the Securities

You should read this pricing supplement together with the prospectus dated November 8, 2024, as supplemented by the prospectus supplement dated November 8, 2024, the underlier supplement dated November 8, 2024 and the product supplement (Market-Linked Notes, Series A) dated November 8, 2024, relating to our Senior Note Program, Series A, of which these securities are a part. Capitalized terms used but not defined in this pricing supplement will have the meanings given to them in the product supplement.

The securities may vary from the terms described in the accompanying prospectus, prospectus supplement, underlier supplement and product supplement in several important ways. You should read this pricing supplement carefully, including the documents incorporated by reference herein. In the event of any conflict between this pricing supplement and any of the foregoing, the following hierarchy will govern: first, this pricing supplement; second, the accompanying product supplement; third, the accompanying underlier supplement; fourth, the accompanying prospectus supplement; and last, the accompanying prospectus. You may access these documents on the SEC website at www.sec.gov as follows (or if that address has changed, by reviewing our filings for the relevant date on the SEC website).

This pricing supplement, together with the documents listed below, contains the terms of the securities and supersedes all prior or contemporaneous oral statements as well as any other written materials including preliminary or indicative pricing terms, correspondence, trade ideas, structures for implementation, sample structures, brochures or other educational materials of ours. You should carefully consider, among other things, the matters set forth in "Risk Factors" herein, in "Additional Risk Factors Specific to the Notes" of the accompanying product supplement and in "Risk Factors" of the accompanying prospectus supplement and of the accompanying prospectus, as the securities involve risks not associated with conventional debt securities.

We urge you to consult your investment, legal, tax, accounting and other advisors concerning an investment in the securities in light of your particular circumstances.

**You may access these documents on the SEC website at www.sec.gov as follows:**

♦Product Supplement (Market-Linked Notes, Series A) dated November 8, 2024:<br>[<u>http://www.sec.gov/Archives/edgar/data/9631/000183988224038316/bns_424b2-21309.htm</u>](http://www.sec.gov/Archives/edgar/data/9631/000183988224038316/bns_424b2-21309.htm)

♦Underlier Supplement dated November 8, 2024:

[<u>http://www.sec.gov/Archives/edgar/data/9631/000183988224038308/bns_424b2-21314.htm</u>](http://www.sec.gov/Archives/edgar/data/9631/000183988224038308/bns_424b2-21314.htm)

♦Prospectus Supplement dated November 8, 2024:

[<u>http://www.sec.gov/Archives/edgar/data/9631/000183988224038303/bns_424b3-21311.htm</u>](http://www.sec.gov/Archives/edgar/data/9631/000183988224038303/bns_424b3-21311.htm)

♦Prospectus dated November 8, 2024:<br>[<u>http://www.sec.gov/Archives/edgar/data/9631/000119312524253771/d875135d424b3.htm</u>](http://www.sec.gov/Archives/edgar/data/9631/000119312524253771/d875135d424b3.htm)

*References to "BNS", "we", "our" and "us" refer only to The Bank of Nova Scotia and not to its consolidated subsidiaries and references to the "securities" refers to the Partial Principal at Risk Securities that are offered hereby. Also, references to the "accompanying product supplement" mean the BNS product supplement, dated November 8, 2024, references to the "accompanying underlier supplement" mean the BNS underlier supplement, dated November 8, 2024, references to the "accompanying prospectus supplement" mean the BNS prospectus supplement, dated November 8, 2024 and references to the "accompanying prospectus" mean the BNS prospectus, dated November 8, 2024.*

BNS reserves the right to change the terms of, or reject any offer to purchase, the securities prior to their issuance. In the event of any changes to the terms of the securities, BNS will notify you and you will be asked to accept such changes in connection with your purchase. You may also choose to reject such changes in which case BNS may reject your offer to purchase.

May 2025 Page 2

------

---

| |
|:---|
| ![](image1.gif)  |
| $3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 |

---

Investment Overview

Partial Principal at Risk Securities

The Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 can be used to achieve similar levels of upside exposure to the underlying index as that of a hypothetical direct investment, subject to the maximum payment at maturity; however, by investing in the securities, you will not be entitled to receive any dividends paid with respect to the stocks comprising the underlying index (the "index constituent stocks") or any interest payments, and your return will not exceed the maximum payment at maturity. You should carefully consider whether an investment that does not provide for any dividends, interest payments or exposure to the positive performance of the underlying index beyond a value that exceeds the maximum gain is appropriate for you.

The securities are exposed on a 1:1 basis to the negative performance of the underlying index, subject to the minimum payment at maturity of $950.00 per security. All payments on the securities are subject to the credit risk of BNS.

---

| | |
|:---|:---|
| &nbsp;&nbsp; **Maturity:** | &nbsp;&nbsp; Approximately 72 months |
| &nbsp;&nbsp; **Maximum payment at maturity:** | &nbsp;&nbsp; $1,705.80 per security (170.58% of the stated principal amount) |
| &nbsp;&nbsp; **Maximum gain:** | &nbsp;&nbsp; 70.58% |
| &nbsp;&nbsp; **Coupon:** |  |
| &nbsp;&nbsp; **Minimum payment at maturity:** | &nbsp;&nbsp; $950.00 (95.00% of the stated principal amount). |
| &nbsp;&nbsp; **Listing:** | &nbsp;&nbsp; The securities will not be listed or displayed on any securities exchange or any electronic communications network |

---

Key Investment Rationale

Investors can use the securities to obtain upside exposure to the underlying index, up to the maximum gain, and maintain 1:1 downside exposure to any decrease in the value of the underlying index, subject to the minimum payment at maturity of $950.00 per security and the credit risk of BNS.

At maturity, investors will receive an amount in cash based upon the underlying return. If the final index value is **greater than** the initial index value, investors will receive the stated principal amount of their investment *plus* a return reflecting the upside performance of the underlying index, subject to the maximum payment at maturity. If the final index value is **less than or equal to** the initial index value, investors will lose 1% for every 1% that the final index value falls below the initial index value, subject to the minimum payment at maturity. Investors may lose up to 5.00% of their investment in the securities. **All payments on the securities are subject to the credit risk of BNS.** 

Investors will not be entitled to receive any dividends paid with respect to the index constituent stocks and the securities do not pay periodic interest. You should carefully consider whether an investment that does not provide for any dividends or periodic interest is appropriate for you.

---

| | |
|:---|:---|
| &nbsp;&nbsp; **Upside Scenario**  | &nbsp;&nbsp;&nbsp; If the final index value is **greater than** the initial index value, at maturity you will receive the stated principal amount of $1,000.00 plus the supplemental redemption amount, subject to the maximum payment at maturity of $1,705.80 per security (170.58% of the stated principal amount).  |
| &nbsp;&nbsp; **Par Scenario**  | &nbsp;&nbsp;&nbsp; If the final index value is **equal to** the initial index value, at maturity you will receive the stated principal amount.  |
| &nbsp;&nbsp; **Downside Scenario** | &nbsp;&nbsp;&nbsp; If the final index value is **less than** the initial index value, at maturity you will lose 1% for every 1% that the final index value falls below the initial index value, subject to the minimum payment at maturity. For example, if the underlying return is -3%, each security will redeem for $970.00, or 97% of the stated principal amount. Alternatively, if the underlying return is -15%, each security will redeem for $950.00, or 95.00% of the stated principal amount. **You could lose up to 5.00% of your investment in the securities.** |

---

May 2025 Page 3

------

---

| |
|:---|
| ![](image1.gif)  |
| $3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 |

---

Investor Suitability

**The securities may be suitable for you if:** 

■You fully understand and are willing to accept the risks of an investment in the securities, including the risk that you may lose up to 5% of your investment in the securities

■You believe that the final index value will be greater than the initial index value and you understand and accept that any positive return that you earn on the securities will not exceed the maximum gain

■You can tolerate fluctuations in the market prices of the securities prior to maturity that may be similar to or exceed the fluctuations in the value of the underlying index

■You do not seek current income from your investment and are willing to forgo any dividends paid on the index constituent stocks

■You are willing and able to hold the securities to maturity, a term of approximately 72 months, and accept that there may be little or no secondary market for the securities

■You understand and are willing to accept the risks associated with the underlying index

■You are willing to assume the credit risk of BNS for all payments under the securities, and you understand that if BNS defaults on its obligations you may not receive any amounts due to you, including any repayment of principal

**The securities may not be suitable for you if:** 

■You do not fully understand or are unwilling to accept the risks of an investment in the securities, including the risk that you may lose up to 5% of your investment in the securities

■You require an investment that provides full protection against loss of principal

■You believe that the final index value will not be greater than the initial index value

■You seek an investment that has an unlimited return potential or you do not understand or cannot accept that your potential return on the securities is limited to the maximum gain

■You cannot tolerate fluctuations in the market price of the securities prior to maturity that may be similar to or exceed the fluctuations in the value of the underlying index

■You seek current income from your investment or prefer to receive the dividends paid on the index constituent stocks

■You are unable or unwilling to hold the securities to maturity, a term of approximately 72 months, or seek an investment for which there will be an active secondary market

■You do not understand or are not willing to accept the risks associated with the underlying index

■You are not willing to assume the credit risk of BNS for all payments under the securities, including any repayment of principal

May 2025 Page 4

------

---

| |
|:---|
| ![](image1.gif)  |
| $3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 |

---

How the Securities Work

The below table and examples are based on the following terms and are purely hypothetical (the actual terms of your securities are specified on the cover hereof).

Investors will not be entitled to receive any dividends paid with respect to the index constituent stocks or any periodic interest. You should carefully consider whether an investment that does not provide for any dividends or periodic interest is appropriate for you. All payments on the securities are subject to the credit risk of BNS.

---

| | |
|:---|:---|
| &nbsp;&nbsp; **Stated principal amount:** | &nbsp;&nbsp;&nbsp; $1,000.00 per security |
| &nbsp;&nbsp; **Hypothetical initial index value:** | &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;100.00 |
| &nbsp;&nbsp; **Maximum payment at maturity:** | &nbsp;&nbsp;&nbsp; $1,705.80 per security |
| &nbsp;&nbsp; **Maximum gain:** | &nbsp;&nbsp;&nbsp; 70.58% |
| &nbsp;&nbsp; **Minimum payment at maturity:** | &nbsp;&nbsp;&nbsp; $950.00 (95.00% of the stated principal amount) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp; **Final index value** | &nbsp;&nbsp; **Underlying return** | &nbsp;&nbsp; **Payment at maturity per security** | &nbsp;&nbsp; **Return on the securities** |
| &nbsp;&nbsp; 190.00 | &nbsp;&nbsp; +90.00% | &nbsp;&nbsp; $1705.80 | &nbsp;&nbsp; +70.58% |
| &nbsp;&nbsp; 180.00 | &nbsp;&nbsp; +80.00% | &nbsp;&nbsp; $1705.80 | &nbsp;&nbsp; +70.58% |
| &nbsp;&nbsp; **170.58** | &nbsp;&nbsp; **+70.58%** | &nbsp;&nbsp; **$1705.80** | &nbsp;&nbsp; **+70.58%** |
| &nbsp;&nbsp; 170.00 | &nbsp;&nbsp; +70.00% | &nbsp;&nbsp; $1700.00 | &nbsp;&nbsp; +70.00% |
| &nbsp;&nbsp; 160.00 | &nbsp;&nbsp; +60.00% | &nbsp;&nbsp; $1600.00 | &nbsp;&nbsp; +60.00% |
| &nbsp;&nbsp; 150.00 | &nbsp;&nbsp; +50.00% | &nbsp;&nbsp; $1500.00 | &nbsp;&nbsp; +50.00% |
| &nbsp;&nbsp; 140.00 | &nbsp;&nbsp; +40.00% | &nbsp;&nbsp; $1400.00 | &nbsp;&nbsp; +40.00% |
| &nbsp;&nbsp; 130.00 | &nbsp;&nbsp; +30.00% | &nbsp;&nbsp; $1300.00 | &nbsp;&nbsp; +30.00% |
| &nbsp;&nbsp; 120.00 | &nbsp;&nbsp; +20.00% | &nbsp;&nbsp; $1200.00 | &nbsp;&nbsp; +20.00% |
| &nbsp;&nbsp; 110.00 | &nbsp;&nbsp; +10.00% | &nbsp;&nbsp; $1100.00 | &nbsp;&nbsp; +10.00% |
| &nbsp;&nbsp; **100.00** | &nbsp;&nbsp; **0.00%** | &nbsp;&nbsp; **$1000.00** | &nbsp;&nbsp; **0.00%** |
| &nbsp;&nbsp; 98.00 | &nbsp;&nbsp; -2.00% | &nbsp;&nbsp; $980.00 | &nbsp;&nbsp; -2.00% |
| &nbsp;&nbsp; 96.00 | &nbsp;&nbsp; -4.00% | &nbsp;&nbsp; $960.00 | &nbsp;&nbsp; -4.00% |
| &nbsp;&nbsp; **95.00** | &nbsp;&nbsp; **-5.00%** | &nbsp;&nbsp; **$950.00** | &nbsp;&nbsp; **-5.00%** |
| &nbsp;&nbsp; 90.00 | &nbsp;&nbsp; -10.00% | &nbsp;&nbsp; $950.00 | &nbsp;&nbsp; -5.00% |
| &nbsp;&nbsp; 80.00 | &nbsp;&nbsp; -20.00% | &nbsp;&nbsp; $950.00 | &nbsp;&nbsp; -5.00% |
| &nbsp;&nbsp; 70.00 | &nbsp;&nbsp; -30.00% | &nbsp;&nbsp; $950.00 | &nbsp;&nbsp; -5.00% |
| &nbsp;&nbsp; 60.00 | &nbsp;&nbsp; -40.00% | &nbsp;&nbsp; $950.00 | &nbsp;&nbsp; -5.00% |
| &nbsp;&nbsp; 50.00 | &nbsp;&nbsp; -50.00% | &nbsp;&nbsp; $950.00 | &nbsp;&nbsp; -5.00% |
| &nbsp;&nbsp; 25.00 | &nbsp;&nbsp; -75.00% | &nbsp;&nbsp; $950.00 | &nbsp;&nbsp; -5.00% |
| &nbsp;&nbsp; 0.00 | &nbsp;&nbsp; -100.00% | &nbsp;&nbsp; $950.00 | &nbsp;&nbsp; -5.00% |

---

**EXAMPLE 1: The underlying index increases over the term of the securities and the payment at maturity is less than the maximum payment at maturity.**

---

| | |
|:---|:---|
| &nbsp;&nbsp; Final index value | &nbsp;&nbsp; 110.00 |
| &nbsp;&nbsp; Underlying return | &nbsp;&nbsp; (110.00 – 100.00) / 100.00 = 10.00% |
| &nbsp;&nbsp; Payment at maturity | &nbsp;&nbsp; = $1,000.00 + supplemental redemption amount, subject to the maximum payment at maturity |
|  | &nbsp;&nbsp; = $1,000.00 + ($1,000.00 × underlying return), subject to the maximum payment at maturity  |
|  | &nbsp;&nbsp; = $1,000.00 + ($1,000.00 × 10.00%), subject to the maximum payment at maturity  |
|  | &nbsp;&nbsp; = $1,100.00  |

---

In **Example 1**, the final index value is greater than the initial index value and the underlying return is 10.00%. Accordingly, investors receive the stated principal amount at maturity plus a return equal to the underlying return, resulting in a payment at maturity of $1,100.00 per security (a total return of 10.00%).

May 2025 Page 5

------

---

| |
|:---|
| ![](image1.gif)  |
| $3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 |

---

**EXAMPLE 2: The underlying index increases over the term of the securities such that the payment at maturity is equal to the maximum payment at maturity.**

---

| | |
|:---|:---|
| &nbsp;&nbsp; Final index value | &nbsp;&nbsp; 180.00 |
| &nbsp;&nbsp; Underlying return | &nbsp;&nbsp; (180.00 – 100.00) / 100.00 = 80.00% |
| &nbsp;&nbsp; Payment at maturity | &nbsp;&nbsp; = $1,000.00 + supplemental redemption amount, subject to the maximum payment at maturity |
|  | &nbsp;&nbsp; = $1,000.00 + ($1,000.00 × underlying return), subject to the maximum payment at maturity  |
|  | &nbsp;&nbsp; = maximum payment at maturity of $1,705.80 per security<br>|

---

In **Example 2**, the final index value is greater than the initial index value and the underlying return is 80.00%. Under the terms of the securities, investors will realize the maximum payment at maturity if the underlying return is 70.58% or higher. Therefore, in this example, investors receive the maximum payment at maturity of $1,705.80 per security even though the underlying index has appreciated by an amount significantly greater than the return represented by the maximum payment at maturity.

**EXAMPLE 3: The final index value is less than the initial index value but the payment at maturity is greater than the minimum payment at maturity.**

---

| | |
|:---|:---|
| &nbsp;&nbsp; Final index value | &nbsp;&nbsp; 97.00 |
| &nbsp;&nbsp; Underlying return | &nbsp;&nbsp; (97.00 – 100.00) / 100.00 = -3.00% |
| &nbsp;&nbsp; Payment at maturity | &nbsp;&nbsp; = $1,000.00 + ($1,000.00 × underlying return), subject to the minimum payment at maturity  |
|  | &nbsp;&nbsp; = $970.00 |

---

In **Example 3**, the final index value is less than the initial index value and the underlying return is -3.00%. Because the final index value is less than the initial index value but the underlying return is not less than -5.00%, investors are fully exposed to the negative performance of the underlying index, resulting in a payment at maturity of $970.00 per security (a total return of -3.00%).

**EXAMPLE 4: The underlying index decreases over the term of the securities such that the payment at maturity is equal to the minimum payment at maturity.**

---

| | |
|:---|:---|
| &nbsp;&nbsp; Final index value | &nbsp;&nbsp; 80.00 |
| &nbsp;&nbsp; Underlying return | &nbsp;&nbsp; (80.00 – 100.00) / 100.00 = -20.00% |
| &nbsp;&nbsp; Payment at maturity | &nbsp;&nbsp; = $1,000.00 + ($1,000.00 × underlying return), subject to the minimum payment at maturity  |
|  | &nbsp;&nbsp; = $950.00 |

---

In **Example 4**, the final index value is less than the initial index value and the underlying return is -20.00%. Because the underlying return is less than the return represented by the minimum payment at maturity, investors receive a payment at maturity of $950.00 per security (a total return of -5.00%).

**If the final index value is less than the initial index value, you will lose 1% for every 1% that the final index value falls below the initial index value, provided that the payment at maturity will not be less than the minimum payment at maturity. Accordingly, you could lose up to 5.00% of your investment in the securities.**

May 2025 Page 6

------

---

| |
|:---|
| ![](image1.gif)  |
| $3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 |

---

Risk Factors

*The following is a non-exhaustive list of certain key risk factors for investors in the securities. For further discussion of these and other risks, you should read the section entitled "Additional Risk Factors Specific to the Notes" of the accompanying product supplement and "Risk Factors" of the accompanying prospectus supplement and of the accompanying prospectus. We also urge you to consult your investment, legal, tax, accounting and other advisors concerning an investment in the securities.*

***Risks Relating to Return Characteristics***

￭**You may receive no positive return and the securities provide for a minimum payment at maturity of only 95.00% of the stated principal amount.** The securities differ from ordinary debt securities in that they provide for a minimum payment at maturity of only 95.00% of the stated principal amount. If the final index value is equal to the initial index value, you will not earn any positive return and, if the final index value is less than the initial index value, you will also lose 1% of the stated principal amount for every 1% that the final index value falls below the initial index value, subject to the minimum payment at maturity. **You may lose up to 5.00% of your investment in the securities.**

￭**The** **stated payout from the issuer applies only at maturity.** You should be willing to hold your securities to maturity. The stated payout is available only if you hold your securities to maturity. If you are able to sell your securities prior to maturity in the secondary market, you may have to sell them at a loss relative to your investment in the securities even if the then-current value of the underlying index is equal to or greater than the initial index value. **All payments on the securities are subject to the credit risk of BNS.**

■**Your potential return on the securities is limited to the maximum gain.** The return potential of the securities is limited to the maximum gain. Therefore, you will not benefit from any positive underlying return in excess of an amount that exceeds the maximum gain. Your return on the securities may be less than that of a hypothetical direct investment in the underlying index or the index constituent stocks.

￭**You will not receive any interest payments.** BNS will not pay any interest with respect to the securities.

■**The amount payable on the securities is not linked to the value of the underlying index at any time other than the valuation date.** The final index value will be based on the index closing value on the valuation date, subject to postponement for non-trading days and certain market disruption events. If the value of the underlying index falls on the valuation date, the payment at maturity may be significantly less than it would have been had the payment at maturity been linked to the value of the underlying index at any time prior to such drop. Although the index closing value on the maturity date or at other times during the term of the securities may be higher than the index closing value on the valuation date, the payment at maturity will be based solely on the index closing value on the valuation date.

■**Owning the securities is not the same as owning the index constituent stocks.** The return on your securities may not reflect the return you would realize if you actually owned the index constituent stocks. For instance, you will not benefit from any positive underlying return that is greater than the maximum gain. Furthermore, you will not receive or be entitled to receive any dividend payments or other distributions paid on the index constituent stocks, and any such dividends or distributions will not be factored into the calculation of the payment at maturity on your securities. In addition, as an owner of the securities, you will not have voting rights or any other rights that a holder of the index constituent stocks may have.

***Risks Relating to Characteristics of the Underlying Index***

￭**An** **investment in the securities involves market risk associated with the underlying index.** The return on the securities, which may be negative, is linked to the performance of the underlying index and indirectly linked to the value of the index constituent stocks. The value of the underlying index can rise or fall sharply due to factors specific to the underlying index or its index constituent stocks and their issuers (the "index constituent stock issuers"), such as stock or commodity price volatility, earnings, financial conditions, corporate, industry and regulatory developments, management changes and decisions and other events, as well as general market factors, such as general stock market or commodity market volatility and values, interest rates and economic, political and other conditions. You, as an investor in the securities, should make your own investigation into the underlying index and the index constituent stocks.

■**There can be no assurance that the investment view implicit in the securities will be successful.** It is impossible to predict whether and the extent to which the value of the underlying index will rise or fall and there can be no assurance that the underlying return will be positive. The final index value (and therefore the underlying return) will be influenced by complex and interrelated political, economic, financial and other factors that affect the index constituent stock issuers. You should be willing to accept the risks associated with the relevant markets tracked by the underlying index in general and each index constituent stock in particular, and the risk of losing up to 5.00% of your investment in the securities.

May 2025 Page 7

------

---

| |
|:---|
| ![](image1.gif)  |
| $3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 |

---

■**The underlying index reflects price return, not total return.** The return on the securities is based on the performance of the underlying index, which reflects the changes in the market prices of the index constituent stocks. It is not, however, linked to a "total return" index or strategy, which, in addition to reflecting those price returns, would also reflect any dividends paid on the index constituent stocks. The return on the securities will not include such a total return feature or dividend component.

■**Changes affecting the underlying index could have an adverse effect on the market value of, and any amount payable on, the securities.** The policies of the index sponsor as specified under "Information About the Underlying Index" (the "index sponsor"), concerning additions, deletions and substitutions of the index constituent stocks and the manner in which the index sponsor takes account of certain changes affecting those index constituent stocks may adversely affect the value of the underlying index. The policies of the index sponsor with respect to the calculation of the underlying index could also adversely affect the value of the underlying index. The index sponsor may discontinue or suspend calculation or dissemination of the underlying index. Any such actions could have an adverse effect on the market value of, and any amount payable on, the securities.

■**There is no affiliation between the index sponsor and BNS, and BNS is not responsible for any disclosure by such index sponsor.** We or our affiliates may currently, or from time to time engage in business with the index sponsor. However, we and our affiliates are not affiliated with the index sponsor and have no ability to control or predict its actions. You, as an investor in the securities, should conduct your own independent investigation of the index sponsor and the underlying index. The index sponsor is not involved in the securities offered hereby in any way and has no obligation of any sort with respect to your securities. The index sponsor has no obligation to take your interests into consideration for any reason, including when taking any actions that might affect the value of, and any amounts payable on, your securities.

***Risks Relating to Estimated Value and Liquidity***

■**BNS' initial estimated value of the securities at the time of pricing (when the terms of your securities were set on the pricing date) is lower than the issue price of the securities. BNS' initial estimated value of the securities is only an estimate**. The issue price of the securities exceeds BNS' initial estimated value. The difference between the issue price of the securities and BNS' initial estimated value reflects costs associated with selling and structuring the securities, as well as hedging its obligations under the securities. Therefore, the economic terms of the securities are less favorable to you than they would have been if these expenses had not been paid or had been lower.

■**Neither BNS' nor SCUSA's estimated value of the securities at any time is determined by reference to credit spreads or the borrowing rate BNS would pay for its conventional fixed-rate debt securities.** BNS' initial estimated value of the securities and SCUSA's estimated value of the securities at any time are determined by reference to BNS' internal funding rate. The internal funding rate used in the determination of the estimated value of the securities generally represents a discount from the credit spreads for BNS' conventional fixed-rate debt securities and the borrowing rate BNS would pay for its conventional fixed-rate debt securities. This discount is based on, among other things, BNS' view of the funding value of the securities as well as the higher issuance, operational and ongoing liability management costs of the securities in comparison to those costs for BNS' conventional fixed-rate debt. If the interest rate implied by the credit spreads for BNS' conventional fixed-rate debt securities, or the borrowing rate BNS would pay for its conventional fixed-rate debt securities were to be used, BNS would expect the economic terms of the securities to be more favorable to you. Consequently, the use of an internal funding rate for the securities increases the estimated value of the securities at any time and has an adverse effect on the economic terms of the securities.

■**BNS' initial estimated value of the securities does not represent future values of the securities and may differ from others' (including SCUSA's) estimates.** BNS' initial estimated value of the securities was determined by reference to its internal pricing models when the terms of the securities were set. These pricing models consider certain factors, such as BNS' internal funding rate on the pricing date, the expected term of the securities, market conditions and other relevant factors existing at that time, and BNS' assumptions about market parameters, which can include volatility of the underlying index, dividend rates, interest rates and other factors. Different pricing models and assumptions (including the pricing models and assumptions used by SCUSA) could provide valuations for the securities that are different, and perhaps materially lower, from BNS' initial estimated value. Therefore, the price at which SCUSA would buy or sell your securities (if SCUSA makes a market, which it is not obligated to do) may be materially lower than BNS' initial estimated value. In addition, market conditions and other relevant factors in the future may change, and any assumptions may prove to be incorrect.

May 2025 Page 8

------

---

| |
|:---|
| ![](image1.gif)  |
| $3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 |

---

■**The securities have limited liquidity.** The securities will not be listed on any securities exchange or automated quotation system. Therefore, there may be little or no secondary market for the securities. SCUSA and any other affiliates of BNS intend, but are not required, to make a market in the securities. Even if there is a secondary market, it may not provide enough liquidity to allow you to trade or sell the securities easily. Because we do not expect that other broker-dealers will participate in the secondary market for the securities, the price at which you may be able to trade your securities is likely to depend on the price, if any, at which SCUSA is willing to purchase the securities from you. If at any time SCUSA does not make a market in the securities, it is likely that there would be no secondary market for the securities. Accordingly, you should be willing to hold your securities to maturity.

■**The price at which SCUSA would buy or sell your securities (if SCUSA makes a market, which it is not obligated to do) will be based on SCUSA's estimated value of your securities.** SCUSA's estimated value of the securities is determined by reference to its pricing models and takes into account BNS' internal funding rate. The price at which SCUSA would initially buy or sell your securities in the secondary market (if SCUSA makes a market, which it is not obligated to do) exceeds SCUSA's estimated value of your securities at the time of pricing. As agreed by SCUSA and the distribution participants, this excess is expected to decline to zero over the period specified under "Additional Information About the Securities — Supplemental information regarding plan of distribution (conflicts of interest); secondary markets (if any)". Thereafter, if SCUSA buys or sells your securities it will do so at prices that reflect the estimated value determined by reference to SCUSA's pricing models at that time. The price at which SCUSA will buy or sell your securities at any time also will reflect its then-current bid and ask spread for similar sized trades of structured notes. If SCUSA calculated its estimated value of your securities by reference to BNS' credit spreads or the borrowing rate BNS would pay for its conventional fixed-rate debt securities (as opposed to BNS' internal funding rate), the price at which SCUSA would buy or sell your securities (if SCUSA makes a market, which it is not obligated to do) could be significantly lower.

SCUSA's pricing models consider certain variables, including principally BNS' internal funding rate, interest rates (forecasted, current and historical rates), the volatility of the underlying index, price-sensitivity analysis and the time to maturity of the securities. These pricing models are proprietary and rely in part on certain assumptions about future events, which may prove to be incorrect. As a result, the actual value you would receive if you sold your securities in the secondary market, if any, to others may differ, perhaps materially, from the estimated value of the securities determined by reference to SCUSA's models, taking into account BNS' internal funding rate, due to, among other things, any differences in pricing models or assumptions used by others. See "— The price of the securities prior to maturity will depend on a number of factors and may be substantially less than the stated principal amount" herein.

In addition to the factors discussed above, the value and quoted price of the securities at any time will reflect many factors and cannot be predicted. If SCUSA makes a market in the securities, the price quoted by SCUSA would reflect any changes in market conditions and other relevant factors, including any deterioration in BNS' creditworthiness or perceived creditworthiness. These changes may adversely affect the value of the securities, including the price you may receive for the securities in any market making transaction. To the extent that SCUSA makes a market in the securities, the quoted price will reflect the estimated value determined by reference to SCUSA's pricing models at that time, plus or minus SCUSA's then current bid and ask spread for similar sized trades of structured securities (and subject to the declining excess amount described above).

Furthermore, if you sell your securities, you will likely be charged a commission for secondary market transactions, or the price will likely reflect a dealer discount. This commission or discount will further reduce the proceeds you would receive for your securities in a secondary market sale.

There is no assurance that SCUSA or any other party will be willing to purchase your securities at any price and, in this regard, SCUSA is not obligated to make a market in the securities. See "— The securities have limited liquidity" herein.

■**The price of the securities prior to maturity will depend on a number of factors and may be substantially less than the stated principal amount.** The price at which the securities may be sold prior to maturity will depend on a number of factors. Some of these factors include, but are not limited to: (i) actual or anticipated changes in the value of the underlying index over the full term of the securities, (ii) volatility of the value of the underlying index and the index constituent stocks and the market's perception of future volatility of the foregoing, (iii) changes in interest rates generally, (iv) any actual or anticipated changes in our credit ratings or credit spreads, (v) dividend yields on the index constituent stocks and (vi) time remaining to maturity. In particular, because the provisions of the securities relating to the payment at maturity behave like options, the value of the securities will vary in ways which are non-linear and may not be intuitive.

Depending on the actual or anticipated value of the underlying index and other relevant factors, the market value of the securities may decrease and you may receive substantially less than the stated principal amount if you sell your securities prior to maturity regardless of the value of the underlying index at such time.

See "Additional Risk Factors Specific to the Notes — Risks Relating to Liquidity — The Market Value of Your Notes May Be Influenced by Many Unpredictable Factors" in the accompanying product supplement.

May 2025 Page 9

------

---

| |
|:---|
| ![](image1.gif)  |
| $3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 |

---

***Risks Relating to General Credit Characteristics***

■**Payments on the securities are subject to the credit risk of BNS.** The securities are senior unsecured debt obligations of BNS and are not, either directly or indirectly, an obligation of any third party. Any payment to be made on the securities, including any repayment of principal, depends on the ability of BNS to satisfy its obligations as they come due. As a result, BNS' actual and perceived creditworthiness may affect the market value of the securities. If BNS were to default on its obligations, you may not receive any amounts owed to you under the terms of the securities and you could lose your entire investment in the securities.

***Risks Relating to Hedging Activities and Conflicts of Interest***

■**Hedging activities by BNS and SCUSA may negatively impact investors in the securities and cause our respective interests and those of our clients and counterparties to be contrary to those of investors in the securities.** We, SCUSA or one or more of our other affiliates has hedged or expects to hedge our obligations under the securities. Such hedging transactions may include entering into swap or similar agreements, purchasing shares of the index constituent stocks and/or purchasing futures, options and/or other instruments linked to the underlying index and/or one or more of the index constituent stocks. We, SCUSA or one or more of our other affiliates also expects to adjust the hedge by, among other things, purchasing or selling any of the foregoing, and perhaps other instruments linked to the underlying index and/or one or more of the index constituent stocks, at any time and from time to time, and to unwind the hedge by selling any of the foregoing on or before the valuation date. We, SCUSA or one or more of our other affiliates may also enter into, adjust and unwind hedging transactions relating to other basket- or index-linked securities whose returns are linked to changes in the value of the underlying index and/or one or more underlying index and/or the index constituent stocks. Any of these hedging activities may adversely affect the value of the underlying index—directly or indirectly by affecting the value of their index constituent stocks — and therefore the market value of the securities and the amount you will receive on the securities.

You should expect that these transactions will cause BNS, SCUSA or our other affiliates, or our clients or counterparties, to have economic interests and incentives that do not align with, and that may be directly contrary to, those of an investor in the securities. None of BNS, SCUSA or any of our other affiliates will have any obligation to take, refrain from taking or cease taking any action with respect to these transactions based on the potential effect on an investor in the securities, and any of the foregoing may receive substantial returns with respect to these hedging activities while the value of, and return on, the securities declines.

■**We, SCUSA and our other affiliates regularly provide services to, or otherwise have business relationships with, a broad client base, which has included and may include us and the index constituent stock issuers and the market activities by us, SCUSA or our other affiliates for our or their own respective accounts or for our clients could negatively impact investors in the securities.** We, SCUSA and our other affiliates regularly provide a wide range of financial services, including financial advisory, investment advisory and transactional services to a substantial and diversified client base. As such, we each may act as an investor, investment banker, research provider, investment manager, investment advisor, market maker, trader, prime broker or lender. In those and other capacities, we, SCUSA and/or our other affiliates purchase, sell or hold a broad array of investments, actively trade securities (including the securities or other securities that we have issued), the index constituent stocks, derivatives, loans, credit default swaps, indices, baskets and other financial instruments and products for our or their own respective accounts or for the accounts of our customers, and we will have other direct or indirect interests, in those securities and in other markets that may not be consistent with your interests and may adversely affect the value of the underlying index and/or the value of the securities. You should assume that we or they will, at present or in the future, provide such services or otherwise engage in transactions with, among others, us and the index constituent stock issuers, or transact in securities or instruments or with parties that are directly or indirectly related to these entities. These services could include making loans to or equity investments in those companies, providing financial advisory or other investment banking services, or issuing research reports. Any of these financial market activities may, individually or in the aggregate, have an adverse effect on the value of the underlying index and the market for your securities, and you should expect that our interests and those of SCUSA and/or our other affiliates, clients or counterparties, will at times be adverse to those of investors in the securities.

You should expect that we, SCUSA, and our other affiliates, in providing these services, engaging in such transactions, or acting for our or their own respective accounts, may take actions that have direct or indirect effects on the securities or other securities that we may issue, the index constituent stocks, other securities or instruments similar to or linked to the foregoing, and that such actions could be adverse to the interests of investors in the securities. In addition, in connection with these activities, certain personnel within us, SCUSA or our other affiliates may have access to confidential material non-public information about these parties that would not be disclosed to investors in the securities.

May 2025 Page 10

------

---

| |
|:---|
| ![](image1.gif)  |
| $3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 |

---

We, SCUSA and our other affiliates regularly offer a wide array of securities, financial instruments and other products into the marketplace, including existing or new products that are similar to the securities or other securities that we may issue, the index constituent stocks or other securities or instruments similar to or linked to the foregoing. Investors in the securities should expect that we, SCUSA and our other affiliates offer securities, financial instruments, and other products that may compete with the securities for liquidity or otherwise.

■**Activities conducted by BNS and its affiliates may impact the value of the underlying index and the value of the securities.** Trading or transactions by BNS, SCUSA or our other affiliates in the underlying index or any index constituent stocks, listed and/or over-the-counter options, futures, exchange-traded funds or other instruments with returns linked to the performance of the underlying index or any index constituent stocks may adversely affect the value of the underlying index or index constituent stocks and, therefore, the market value of the securities. See "— Hedging activities by BNS and SCUSA may negatively impact investors in the securities and cause our respective interests and those of our clients and counterparties to be contrary to those of investors in the securities" for additional information regarding hedging-related transactions and trading.

■**The calculation agent will have significant discretion with respect to the securities, which may be exercised in a manner that is adverse to your interests.** The calculation agent will be an affiliate of BNS. The calculation agent will determine the payment at maturity of the securities based on the observed final index value. The calculation agent can postpone the determination of the final index value (and therefore the related maturity date) if a market disruption event occurs and is continuing with respect to the underlying index on the valuation date.

■**BNS** **and its affiliates may publish research or make opinions or recommendations that are inconsistent with an investment in the securities.** BNS, SCUSA and our other affiliates may publish research from time to time on financial markets and other matters that may influence the value of the securities, or express opinions or provide recommendations that are inconsistent with purchasing or holding the securities. Any research, opinions or recommendations expressed by BNS, SCUSA or our other affiliates may not be consistent with each other and may be modified from time to time without notice. Investors should make their own independent investigation of the merits of investing in the securities and the underlying index to which the securities are linked.

***Risks Relating to Canadian and U.S. Federal Income Taxation***

■**Because the securities are subject to special rules governing CPDI for U.S. federal income tax purposes, you generally will be required to pay taxes on ordinary income from the securities even though you will not receive any payment on the securities prior to the maturity date.** If you are a U.S. holder, you generally will be required to pay taxes on ordinary income from the securities over their term based on the comparable yield for the securities, even though you will not receive any payment on the securities until the maturity date. This comparable yield is determined solely to calculate the amount on which you will be taxed prior to the maturity date and is neither a prediction nor a guarantee of what the actual yield will be. In addition, any gain you may recognize on the taxable disposition of the securities will be taxed as ordinary interest income. If you purchased the securities in the secondary market, the tax consequences to you may be different. Please see "Additional Information About the Securities — Tax Considerations" herein for a more detailed discussion. Please also consult your tax advisor concerning the U.S. federal income tax and any other applicable tax consequences to you of owning your securities in your particular circumstances.

■**Uncertain tax treatment.** Significant aspects of the tax treatment of the securities are uncertain. You should consult your tax advisor about your tax situation. See "Additional Information About the Securities — Tax Considerations" and "— Material Canadian Income Tax Consequences" herein.

May 2025 Page 11

------

---

| |
|:---|
| ![](image1.gif)  |
| $3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 |

---

Information About the Underlying Index

**All disclosures contained in this document regarding the underlying index are derived from publicly available information. BNS has not conducted any independent review or due diligence of any publicly available information with respect to the underlying index. You should make your own investigation into the underlying index.**

**S&P 500**<sup>®</sup> **Index**

We have derived all information contained herein regarding the underlying index, including without limitation, its make-up, method of calculation and changes in its components from publicly available information. Such information reflects the policies of, and is subject to change by, S&P Dow Jones Indices LLC (the "index sponsor"), and/or its affiliates.

The underlying index includes a representative sample of 500 companies in leading industries of the U.S. economy and is intended to provide a performance benchmark for the large-cap U.S. equity markets. Please see "Indices—The S&P 500<sup>®</sup> Index" in the accompanying underlier supplement for additional information regarding the underlying index, the index sponsor and our license agreement with respect to the underlying index. Additional information regarding the underlying index, including its sectors, sector weightings and top constituents, may be available on the index sponsor's website.

**Information as of market close on May 30, 2025:**

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp; **Bloomberg Ticker Symbol:** | &nbsp;&nbsp; SPX  | &nbsp;&nbsp; **52 Week High (on February 19, 2025):** | &nbsp;&nbsp; 6144.15 |
| &nbsp;&nbsp; **Current Index Value:** | &nbsp;&nbsp; 5911.69 | &nbsp;&nbsp; **52 Week Low (on April 8, 2025):** | &nbsp;&nbsp; 4982.77 |
| &nbsp;&nbsp; **52 Weeks Ago (on May 30, 2024):** | &nbsp;&nbsp; 5235.48 |  |  |

---

May 2025 Page 12

------

---

| |
|:---|
| ![](image1.gif)  |
| $3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 |

---

Historical Information

The table below sets forth the published high and low index closing values, as well as the end-of-quarter index closing values, of the underlying index for the specified period. The index closing value of the underlying index on May 30, 2025 was 5,911.69. The graph below sets forth the index closing values of the underlying index for each day from January 1, 2020 through May 30, 2025. We obtained the information in the table below from Bloomberg Professional<sup>®</sup> service ("Bloomberg"), without independent verification. BNS has not undertaken an independent review or due diligence of any publicly available information obtained from Bloomberg. *The historical performance of the underlying index should not be taken as an indication of its future performance, and no assurance can be given as to the index closing value of the underlying index at any time, including the valuation date.*

---

| | | | |
|:---|:---|:---|:---|
|  **S&P 500**<sup>®</sup> **Index** | **High** | **Low** | **Period End** |
| **2020** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First Quarter | 3386.15 | 2237.40 | 2584.59 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Second Quarter | 3232.39 | 2470.50 | 3100.29 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Third Quarter | 3580.84 | 3115.86 | 3363.00 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fourth Quarter | 3756.07 | 3269.96 | 3756.07 |
| **2021** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First Quarter | 3974.54 | 3700.65 | 3972.89 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Second Quarter | 4297.50 | 4019.87 | 4297.50 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Third Quarter | 4536.95 | 4258.49 | 4307.54 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fourth Quarter  | 4793.06 | 4300.46 | 4766.18 |
| **2022** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First Quarter  | 4796.56 | 4170.70 | 4530.41 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Second Quarter  | 4582.64 | 3666.77 | 3785.38 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Third Quarter | 4305.20 | 3585.62 | 3585.62 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fourth Quarter | 4080.11 | 3577.03 | 3839.50 |
| **2023** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First Quarter | 4179.76 | 3808.10 | 4109.31 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Second Quarter | 4450.38 | 4055.99 | 4450.38 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Third Quarter | 4588.96 | 4273.53 | 4288.05 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fourth Quarter  | 4783.35 | 4117.37 | 4769.83 |
| **2024** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First Quarter | 5254.35 | 4688.68 | 5254.35 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Second Quarter | 5487.03 | 4967.23 | 5460.48 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Third Quarter  | 5762.48 | 5186.33 | 5762.48 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fourth Quarter | 6090.27 | 5695.94 | 5881.63 |
| **2025** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First Quarter | 6144.15 | 5521.52 | 5611.85 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Second Quarter (through May 30, 2025) | 5963.60 | 4982.77 | 5911.69 |

---

May 2025 Page 13

------

---

| |
|:---|
| ![](image1.gif)  |
| $3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 |

---

&nbsp;&nbsp; **S** **&P 500**<sup>®</sup> **Index – Daily Index closing values**<br> **January 1, 2020 to May 30, 2025** <br>

**This document relates only to the securities offered hereby and does not relate to the underlying index or other securities linked to the underlying index. We have derived all disclosures contained in this document regarding the underlying index from the publicly available documents described in the preceding paragraphs. In connection with the offering of the securities, none of us or any of our affiliates have participated in the preparation of such documents or made any due diligence inquiry with respect to the underlying index.** 

Neither the issuer nor any of its affiliates makes any representation to you as to the performance of the underlying index.

May 2025 Page 14

------

---

| |
|:---|
| ![](image1.gif)  |
| $3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 |

---

Additional Information About the Securities

Please read this information in conjunction with the summary terms on the front cover of this document.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; **Additional Provisions:** | &nbsp;&nbsp; **Additional Provisions:** | &nbsp;&nbsp; **Additional Provisions:** |
| &nbsp;&nbsp; **Trustee:** | &nbsp;&nbsp;&nbsp; Computershare Trust Company, N.A. | &nbsp;&nbsp;&nbsp; Computershare Trust Company, N.A. |
| &nbsp;&nbsp; **Calculation agent:** | &nbsp;&nbsp;&nbsp; Scotia Capital Inc. | &nbsp;&nbsp;&nbsp; Scotia Capital Inc. |
| &nbsp;&nbsp; **Trading day:** | &nbsp;&nbsp;&nbsp; As specified in the product supplement under "General Terms of the Notes — Special Calculation Provisions — Trading Day". | &nbsp;&nbsp;&nbsp; As specified in the product supplement under "General Terms of the Notes — Special Calculation Provisions — Trading Day". |
| &nbsp;&nbsp; **Business day:** | &nbsp;&nbsp;&nbsp; As specified in the product supplement under "General Terms of the Notes — Special Calculation Provisions — Business Day". | &nbsp;&nbsp;&nbsp; As specified in the product supplement under "General Terms of the Notes — Special Calculation Provisions — Business Day". |
| &nbsp;&nbsp; **Tax redemption:** | &nbsp;&nbsp;&nbsp; Notwithstanding anything to the contrary in the accompanying product supplement, the provisions set forth under "General Terms of the Notes — Payment of Additional Amounts" and "General Terms of the Notes — Tax Redemption" shall not apply to the securities. | &nbsp;&nbsp;&nbsp; Notwithstanding anything to the contrary in the accompanying product supplement, the provisions set forth under "General Terms of the Notes — Payment of Additional Amounts" and "General Terms of the Notes — Tax Redemption" shall not apply to the securities. |
| &nbsp;&nbsp; **Canadian bail-in:** | &nbsp;&nbsp;&nbsp; The securities are not bail-inable debt securities under the CDIC Act. | &nbsp;&nbsp;&nbsp; The securities are not bail-inable debt securities under the CDIC Act. |
| &nbsp;&nbsp; **Terms incorporated:** | &nbsp;&nbsp;&nbsp; All of the terms appearing above the item under the caption "General Terms of the Notes" in the accompanying product supplement, as modified by this document, and for purposes of the foregoing, the terms used herein mean the corresponding terms as defined in the accompanying product supplement, as specified below: | &nbsp;&nbsp;&nbsp; All of the terms appearing above the item under the caption "General Terms of the Notes" in the accompanying product supplement, as modified by this document, and for purposes of the foregoing, the terms used herein mean the corresponding terms as defined in the accompanying product supplement, as specified below: |
| &nbsp;&nbsp; **Terms incorporated:** | &nbsp;&nbsp; *<u>Term used herein</u>* | &nbsp;&nbsp; *<u>Corresponding term in the accompanying product supplement</u>* |
| &nbsp;&nbsp; **Terms incorporated:** | &nbsp;&nbsp;&nbsp; underlying index | &nbsp;&nbsp;&nbsp; reference asset |
| &nbsp;&nbsp; **Terms incorporated:** | &nbsp;&nbsp;&nbsp; index constituent stocks | &nbsp;&nbsp;&nbsp; reference asset constituents |
| &nbsp;&nbsp; **Terms incorporated:** | &nbsp;&nbsp;&nbsp; stated principal amount | &nbsp;&nbsp;&nbsp; principal amount |
| &nbsp;&nbsp; **Terms incorporated:** | &nbsp;&nbsp;&nbsp; original issue date | &nbsp;&nbsp;&nbsp; issue date |
| &nbsp;&nbsp; **Terms incorporated:** | &nbsp;&nbsp;&nbsp; valuation date | &nbsp;&nbsp;&nbsp; final valuation date |
| &nbsp;&nbsp; **Terms incorporated:** | &nbsp;&nbsp;&nbsp; index closing value | &nbsp;&nbsp;&nbsp; closing value |
| &nbsp;&nbsp; **Terms incorporated:** | &nbsp;&nbsp;&nbsp; initial index value | &nbsp;&nbsp;&nbsp; initial value |
| &nbsp;&nbsp; **Terms incorporated:** | &nbsp;&nbsp;&nbsp; final index value | &nbsp;&nbsp;&nbsp; final value |
| &nbsp;&nbsp; **Terms incorporated:** | &nbsp;&nbsp;&nbsp; underlying return | &nbsp;&nbsp;&nbsp; reference asset return |
| &nbsp;&nbsp; **Additional information regarding estimated value of the securities:** | &nbsp;&nbsp;&nbsp; On the cover page of this pricing supplement, BNS has provided the initial estimated value for the securities. The initial estimated value was determined by reference to BNS' internal pricing models, which take into consideration certain factors, such as BNS' internal funding rate on the pricing date and BNS' assumptions about market parameters. For more information about the initial estimated value, see "Risk Factors — Risks Relating to Estimated Value and Liquidity" herein.<br> The economic terms of the securities are based on BNS' internal funding rate, which is the rate BNS would pay to borrow funds through the issuance of similar market-linked securities and the economic terms of certain related hedging arrangements. Due to these factors, the issue price you pay to purchase the securities is greater than the initial estimated value of the securities. BNS' internal funding rate is typically lower than the rate BNS would pay when it issues conventional fixed rate debt securities as discussed further under "Risk Factors — Risks Relating to Estimated Value and Liquidity — Neither BNS' nor SCUSA's estimated value of the securities at any time is determined by reference to credit spreads or the borrowing rate BNS would pay for its conventional fixed-rate debt securities". BNS' use of its internal funding rate reduces the economic terms of the securities to you. **We urge you to read the "Risk Factors" in this pricing supplement for additional information.** | &nbsp;&nbsp;&nbsp; On the cover page of this pricing supplement, BNS has provided the initial estimated value for the securities. The initial estimated value was determined by reference to BNS' internal pricing models, which take into consideration certain factors, such as BNS' internal funding rate on the pricing date and BNS' assumptions about market parameters. For more information about the initial estimated value, see "Risk Factors — Risks Relating to Estimated Value and Liquidity" herein.<br> The economic terms of the securities are based on BNS' internal funding rate, which is the rate BNS would pay to borrow funds through the issuance of similar market-linked securities and the economic terms of certain related hedging arrangements. Due to these factors, the issue price you pay to purchase the securities is greater than the initial estimated value of the securities. BNS' internal funding rate is typically lower than the rate BNS would pay when it issues conventional fixed rate debt securities as discussed further under "Risk Factors — Risks Relating to Estimated Value and Liquidity — Neither BNS' nor SCUSA's estimated value of the securities at any time is determined by reference to credit spreads or the borrowing rate BNS would pay for its conventional fixed-rate debt securities". BNS' use of its internal funding rate reduces the economic terms of the securities to you. **We urge you to read the "Risk Factors" in this pricing supplement for additional information.** |
| &nbsp;&nbsp; **Material Canadian income tax consequences:** | &nbsp;&nbsp;&nbsp; See "Supplemental Discussion of Canadian Tax Consequences" in the accompanying product supplement. In addition to the assumptions, limitations and conditions described therein, such discussion assumes that no amount paid or payable to a Non-Resident Holder will be the deduction component of a "hybrid mismatch arrangement" under which the payment arises within the meaning of paragraph 18.4(3)(b) of the Act.  | &nbsp;&nbsp;&nbsp; See "Supplemental Discussion of Canadian Tax Consequences" in the accompanying product supplement. In addition to the assumptions, limitations and conditions described therein, such discussion assumes that no amount paid or payable to a Non-Resident Holder will be the deduction component of a "hybrid mismatch arrangement" under which the payment arises within the meaning of paragraph 18.4(3)(b) of the Act.  |
| &nbsp;&nbsp; **Tax considerations:** | &nbsp;&nbsp;&nbsp; **The U.S. federal income tax consequences of your investment in the securities are uncertain. There are no statutory provisions, regulations, published rulings or judicial decisions addressing the characterization for U.S. federal income tax purposes of securities with terms that are substantially the same as the securities. Some of these tax consequences are summarized below, but we urge you to read the more detailed discussion in "Material U.S. Federal Income Tax Consequences", in the accompanying product supplement and to discuss the tax consequences of your particular situation with your tax advisor. This discussion is based upon the U.S. Internal Revenue Code of 1986, as amended (the "Code"), final, temporary and proposed U.S. Department of the Treasury (the "Treasury") regulations, rulings and decisions, in each case, as available and in effect as of the date hereof, all of which are subject to change, possibly with retroactive effect. Tax consequences under state, local and non-U.S. laws are not addressed herein. No ruling from the U.S. Internal Revenue Service (the "IRS") has been sought as to the U.S. federal income tax consequences of your investment in the securities, and the following discussion is not binding on the IRS.**<br> *U.S. Tax Treatment.* Pursuant to the terms of the securities, BNS and you agree, in the absence of a statutory or regulatory change or an administrative determination or judicial ruling  | &nbsp;&nbsp;&nbsp; **The U.S. federal income tax consequences of your investment in the securities are uncertain. There are no statutory provisions, regulations, published rulings or judicial decisions addressing the characterization for U.S. federal income tax purposes of securities with terms that are substantially the same as the securities. Some of these tax consequences are summarized below, but we urge you to read the more detailed discussion in "Material U.S. Federal Income Tax Consequences", in the accompanying product supplement and to discuss the tax consequences of your particular situation with your tax advisor. This discussion is based upon the U.S. Internal Revenue Code of 1986, as amended (the "Code"), final, temporary and proposed U.S. Department of the Treasury (the "Treasury") regulations, rulings and decisions, in each case, as available and in effect as of the date hereof, all of which are subject to change, possibly with retroactive effect. Tax consequences under state, local and non-U.S. laws are not addressed herein. No ruling from the U.S. Internal Revenue Service (the "IRS") has been sought as to the U.S. federal income tax consequences of your investment in the securities, and the following discussion is not binding on the IRS.**<br> *U.S. Tax Treatment.* Pursuant to the terms of the securities, BNS and you agree, in the absence of a statutory or regulatory change or an administrative determination or judicial ruling  |

---

October 2015 Page 15

------

---

| |
|:---|
| ![](image1.gif)  |
| $3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 |

---

&nbsp;&nbsp;&nbsp; to the contrary, to characterize your securities as contingent payment debt instruments ("CPDI") subject to taxation under the "noncontingent bond method". If your securities are so treated, you should generally, for each accrual period, accrue original issue discount ("OID") equal to the product of (i) the "comparable yield" (adjusted for the length of the accrual period) and (ii) the "adjusted issue price" of the securities at the beginning of the accrual period. This amount is ratably allocated to each day in the accrual period and is includible as ordinary interest income by a U.S. holder for each day in the accrual period on which the U.S. holder holds the CPDI, whether or not the amount of any payment is fixed or determinable in the taxable year. Thus, the noncontingent bond method will result in recognition of income prior to the receipt of cash.<br> In general, the comparable yield of a CPDI is equal to the yield at which we would issue a fixed rate debt instrument with terms and conditions similar to those of the CPDI, including the level of subordination, term, timing of payments, and general market conditions. In general, because similar fixed rate debt instruments issued by us are traded at a price that reflects a spread above a benchmark rate, the comparable yield is the sum of the benchmark rate on the original issue date and the spread. However, a special rule provides that the comparable yield may not be less than the "applicable federal rate" published by the Treasury.<br> As the securities have only a single contingent payment at maturity, the adjusted issue price of each security at the beginning of each accrual period is equal to the issue price of the security plus the amount of OID previously includible in the gross income of the U.S. holder in respect of prior accrual periods.<br> In addition to the determination of a comparable yield, the noncontingent bond method requires the construction of a projected payment schedule. The projected payment schedule includes the projected amount for the contingent payment to be made under the CPDI, adjusted to produce the comparable yield. We have determined that the comparable yield for the securities is equal to 5.00% per annum, compounded semi-annually, with a projected payment at maturity of $1,344.89 based on an investment of $1,000.<br> Based on this comparable yield, if you are an initial holder that holds a security until maturity and you calculate your taxes on a calendar year basis, we have determined that you would be required to report the following amounts as ordinary interest income from the security, not taking into account any positive or negative adjustments you may be required to take into account based on actual payments on such security:<br> \| \| \| \|<br> \|:---\|:---\|:---\|<br> \| Accrual Period \| Interest Deemed to Accrue During Accrual Period (per $1,000 security) \| Total Interest Deemed to Have Accrued From Original Issue Date (per $1,000 security) as of End of Accrual Period \|<br> \| Original Issue Date through December 4, 2025 \| $25.00 \| $25.00 \|<br> \| December 4, 2025 through June 4, 2026 \| $25.63 \| $50.63 \|<br> \| June 4, 2026 through December 4, 2026 \| $26.27 \| $76.89 \|<br> \| December 4, 2026 through June 4, 2027 \| $26.92 \| $103.81 \|<br> \| June 4, 2027 through December 4, 2027 \| $27.60 \| $131.41 \|<br> \| December 4, 2027 through June 4, 2028 \| $28.29 \| $159.69 \|<br> \| June 4, 2028 through December 4, 2028 \| $28.99 \| $188.69 \|<br> \| December 4, 2028 through June 4, 2029 \| $29.72 \| $218.40 \|<br> \| June 4, 2029 through December 4, 2029 \| $30.46 \| $248.86 \|<br> \| December 4, 2029 through June 4, 2030 \| $31.22 \| $280.08 \|<br> \| June 4, 2030 through December 4, 2030 \| $32.00 \| $312.09 \|<br> \| December 4, 2030 through Maturity Date \| $32.80 \| $344.89 \| A U.S. holder of the securities is required to use our projected payment schedule to determine its interest accruals and adjustments, unless such holder determines that our projected payment schedule is unreasonable, in which case such holder must disclose its own projected <br>

October 2015 Page 16

------

---

| |
|:---|
| ![](image1.gif)  |
| $3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 |

---

&nbsp;&nbsp;&nbsp; payment schedule in connection with its U.S. federal income tax return and the reason(s) why it is not using our projected payment schedule. Neither the comparable yield nor the projected payment schedule constitutes a representation by us regarding the actual contingent amount that we will pay on a security.<br> If the actual amount of the contingent payment at maturity is different from the amount reflected in the projected payment schedule, a U.S. holder is required to make adjustments in its OID accruals under the noncontingent bond method described above when that amount is paid. An adjustment arising from the contingent payment made at maturity that is greater than the assumed amount of such payment is referred to as a "positive adjustment"; an adjustment arising from the contingent payment at maturity that is less than the assumed amount of such payment is referred to as a "negative adjustment". Any positive adjustment for a taxable year is treated as additional OID income of the U.S. holder. Any net negative adjustment reduces any OID on a security for the taxable year that would otherwise accrue. Any excess is then treated as a current-year ordinary loss to the U.S. holder to the extent of OID accrued in prior years. <br> In general, a U.S. holder's basis in a CPDI is increased by the projected contingent payments accrued by such holder under the projected payment schedule (as determined without regard to adjustments made to reflect differences between actual and projected payments) and the projected amount of any contingent payments previously made. Gain on the taxable disposition (including cash settlement) of a CPDI generally is treated as ordinary income. Loss, on the other hand, is treated as ordinary loss only to the extent of the U.S. holder's prior net OID inclusions (i.e., reduced by the total net negative adjustments previously allowed to the U.S. holder as an ordinary loss) and capital loss to the extent in excess thereof. However, the deductibility of a capital loss realized on the taxable disposition of a security is subject to limitations. Under the rules governing CPDI, special rules would apply to a person who purchases securities at a price other than the adjusted issue price as determined for tax purposes.<br> A U.S. holder that purchases a security for an amount other than the public offering price of the security will be required to adjust its OID inclusions to account for the difference. These adjustments will affect the U.S. holder's basis in the security. Reports to U.S. holders may not include these adjustments. U.S. holders that purchase securities at other than the issue price to public should consult their tax advisor regarding these adjustments.<br> **Investors should consult their tax advisor with respect to the application of the CPDI provisions to the securities.**<br> **Based on certain factual representations received from us, our special U.S. tax counsel, Fried, Frank, Harris, Shriver & Jacobson LLP, is of the opinion that it would be reasonable to treat your securities in the manner described above.** <br> *Medicare Tax on Net Investment Income*. U.S. holders that are individuals, estates or certain trusts are subject to an additional 3.8% tax on all or a portion of their "net investment income," or "undistributed net investment income" in the case of an estate or trust, which may include any income or gain realized with respect to the securities, to the extent of their net investment income or undistributed net investment income (as the case may be) that, when added to their other modified adjusted gross income, exceeds $200,000 for an unmarried individual, $250,000 for a married taxpayer filing a joint return (or a surviving spouse), $125,000 for a married individual filing a separate return or the dollar amount at which the highest tax bracket begins for an estate or trust. The 3.8% Medicare tax is determined in a different manner than the regular income tax. U.S. holders should consult their tax advisors as to the consequences of the 3.8% Medicare tax.<br> *Specified Foreign Financial Assets.* Certain U.S. holders that own "specified foreign financial assets" in excess of an applicable threshold may be subject to reporting obligations with respect to such assets with their tax returns, especially if such assets are held outside the custody of a U.S. financial institution. U.S. holders are urged to consult their tax advisors as to the application of this legislation to their ownership of the securities.<br> *Non-U.S. Holders.* Subject to Section 871(m) of the Code and "FATCA", discussed below, if you are a non-U.S. holder you should generally not be subject to U.S. withholding tax with respect to payments on your securities or to generally applicable information reporting and backup withholding requirements with respect to payments on your securities if you comply with certain certification and identification requirements as to your non-U.S. status (by providing us (and/or the applicable withholding agent) with a fully completed and duly executed applicable IRS Form W-8). Subject to Section 871(m) of the Code, discussed below, gain realized from the taxable disposition of a security generally should not be subject to U.S. tax unless (i) such gain is effectively connected with a trade or business conducted by you in the U.S., (ii) you are a non-resident alien individual and are present in the U.S. for 183 days or more during the taxable year of such taxable disposition and certain other conditions are satisfied or (iii) you have certain other present or former connections with the U.S.<br> As discussed above, alternative characterizations of the securities for U.S. federal income tax purposes are possible. Should an alternative characterization of the securities cause payments with respect to the securities to become subject to withholding tax, we (or the applicable withholding agent) will withhold tax at the applicable statutory rate and we will not make payments of any additional amounts.<br>

October 2015 Page 17

------

---

| |
|:---|
| ![](image1.gif)  |
| $3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 |

---

&nbsp;&nbsp;&nbsp; *Section 871(m).* A 30% withholding tax (which may be reduced by an applicable income tax treaty) is imposed under Section 871(m) of the Code on certain "dividend equivalents" paid or deemed paid to a non-U.S. holder with respect to a "specified equity-linked instrument" that references one or more dividend-paying U.S. equity securities or indices containing U.S. equity securities. The withholding tax can apply even if the instrument does not provide for payments that reference dividends. Treasury regulations provide that the withholding tax applies to all dividend equivalents paid or deemed paid on specified equity-linked instruments that have a delta of one ("delta-one specified equity-linked instruments") issued after 2016 and to all dividend equivalents paid or deemed paid on all other specified equity-linked instruments issued after 2017. However, the IRS has issued guidance that states that the Treasury and the IRS intend to amend the effective dates of the Treasury regulations to provide that withholding on dividend equivalents paid or deemed paid will not apply to specified equity-linked instruments that are not delta-one specified equity-linked instruments and are issued before January 1, 2027.<br> Based on the nature of the underlying index and our determination that the securities are not "delta-one" with respect to the underlying index or any index constituent stocks, our special U.S. tax counsel is of the opinion that the securities should not be delta-one specified equity-linked instruments and thus should not be subject to withholding on dividend equivalents. Our determination is not binding on the IRS, and the IRS may disagree with this determination. Furthermore, the application of Section 871(m) of the Code will depend on our determinations on the date the terms of the securities are set. If withholding is required, we will not make payments of any additional amounts.<br> Nevertheless, after the date the terms are set, it is possible that your securities could be deemed to be reissued for tax purposes upon the occurrence of certain events affecting an underlying index, any index constituent stocks or your securities, and following such occurrence your securities could be treated as delta-one specified equity-linked instruments that are subject to withholding on dividend equivalents. It is also possible that withholding tax or other tax under Section 871(m) of the Code could apply to the securities under these rules if you enter, or have entered, into certain other transactions in respect of the underlying index, any index constituent stocks or the securities. If you enter, or have entered, into other transactions in respect of the underlying index, any index constituent stocks or the securities, you should consult your tax advisor regarding the application of Section 871(m) of the Code to your securities in the context of your other transactions.<br> **Because of the uncertainty regarding the application of the 30% withholding tax on dividend equivalents to the securities, you are urged to consult your tax advisor regarding the potential application of Section 871(m) of the Code and the 30% withholding tax to an investment in the securities.**<br> *FATCA.* Legislation commonly referred to as the Foreign Account Tax Compliance Act ("FATCA") generally imposes a withholding tax of 30% on payments to certain non-U.S. entities (including financial intermediaries) with respect to certain financial instruments, unless various U.S. information reporting and due diligence requirements have been satisfied. An intergovernmental agreement between the U.S. and the non-U.S. entity's jurisdiction may modify these requirements. This legislation generally applies to certain financial instruments that are treated as paying U.S.-source interest or other U.S.-source "fixed or determinable annual or periodical" income ("FDAP income"). Withholding (if applicable) applies to payments of U.S.-source FDAP income but, pursuant to certain Treasury regulations and IRS guidance, does not apply to payments of gross proceeds on the disposition (including upon retirement) of financial instruments. As the treatment of the securities is unclear, it is possible that any contingent quarterly coupon with respect to the securities could be subject to the FATCA rules. If withholding applies to the securities, we will not be required to pay any additional amounts with respect to amounts withheld. Both U.S. and non-U.S. holders should consult their tax advisors regarding the potential application of FATCA to the securities.<br> *Backup Withholding and Information Reporting.* The proceeds received from a taxable disposition of the securities will be subject to information reporting unless you are an "exempt recipient" and may also be subject to backup withholding at the rate specified in the Code if you fail to provide certain identifying information (such as an accurate taxpayer number, if you are a U.S. holder) or meet certain other conditions.<br> Amounts withheld under the backup withholding rules are not additional taxes and may be refunded or credited against your U.S. federal income tax liability, provided the required information is furnished to the IRS.<br> *U.S. Federal Estate Tax Treatment of Non-U.S. Holders.* A security may be subject to U.S. federal estate tax if an individual non-U.S. holder holds the securities at the time of his or her death. The gross estate of a non-U.S. holder domiciled outside the U.S. includes only property situated in the U.S. Individual non-U.S. holders should consult their tax advisors regarding the U.S. federal estate tax consequences of holding the securities at death.<br> **Both U.S. and non-U.S. holders are urged to consult their tax advisors concerning the application of U.S. federal income tax laws to their particular situations, as well as any tax consequences of the purchase, beneficial ownership and disposition of the securities arising under the laws of any state, local, non-U.S. or other taxing jurisdiction** <br>

October 2015 Page 18

------

---

| |
|:---|
| ![](image1.gif)  |
| $3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 |

---

---

| | |
|:---|:---|
|  | &nbsp;&nbsp; **(including that of BNS).** |
| &nbsp;&nbsp; **Supplemental information regarding plan of distribution (conflicts of interest); secondary markets (if any):** | &nbsp;&nbsp;&nbsp; SCUSA, our affiliate, has agreed to purchase the securities at the stated principal amount and, as part of the distribution of the securities, has agreed to sell the securities to Morgan Stanley Wealth Management with an underwriting discount of $35.00 reflecting a fixed sales commission of $30.00 and fixed structuring fee of $5.00 per $1,000.00 stated principal amount of securities that Morgan Stanley Wealth Management sells. BNS or an affiliate may also pay a fee to LFT Securities, LLC, an entity in which an affiliate of Morgan Stanley Wealth Management has an ownership interest, for providing certain electronic platform services with respect to this offering. |
|  | &nbsp;&nbsp;&nbsp; BNS, SCUSA or any other affiliate of BNS may use this document, the accompanying product supplement and the accompanying prospectus in a market-making transaction for any securities after their initial sale. In connection with the offering, BNS, SCUSA, any other affiliate of BNS or any other securities dealers may distribute this document, the accompanying product supplement and the accompanying prospectus electronically. Unless BNS or its agent informs the purchaser otherwise in the confirmation of sale, this document, the accompanying product supplement and the accompanying prospectus are being used in a market-making transaction. |
|  | &nbsp;&nbsp;&nbsp; **Conflicts of Interest —** SCUSA is an affiliate of BNS and, as such, has a "conflict of interest" in this offering within the meaning of the Financial Industry Regulatory Authority, Inc. ("FINRA") Rule 5121. In addition, BNS will receive the gross proceeds from the initial public offering of the securities, thus creating an additional conflict of interest within the meaning of FINRA Rule 5121. Consequently, the offering is being conducted in compliance with the provisions of FINRA Rule 5121. SCUSA is not permitted to sell securities in this offering to an account over which it exercises discretionary authority without the prior specific written approval of the account holder.<br> In the ordinary course of their various business activities, SCUSA, and its affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments of BNS. SCUSA, and its affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.  |
|  | &nbsp;&nbsp;&nbsp; **SCUSA and its affiliates may offer to buy or sell the securities in the secondary market (if any) at prices greater than BNS' internal valuation —** The value of the securities at any time will vary based on many factors that cannot be predicted. However, the price (not including SCUSA's or any affiliates' customary bid-ask spreads) at which SCUSA or any affiliate would offer to buy or sell the securities immediately after the pricing date in the secondary market is expected to exceed the initial estimated value of the securities as determined by reference to our internal pricing models. The amount of the excess will decline to zero on a straight line basis over a period ending no later than 6 weeks after the pricing date, provided that SCUSA may shorten the period based on various factors, including the magnitude of purchases and other negotiated provisions with selling agents. Notwithstanding the foregoing, SCUSA and its affiliates intend, but are not required, to make a market for the securities and may stop making a market at any time. For more information about secondary market offers and the initial estimated value of the securities, see "Risk Factors" herein. |
| &nbsp;&nbsp;&nbsp; **Prohibition of sales to EEA retail investors**: | &nbsp;&nbsp;&nbsp; The securities are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area ("EEA"). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU, as amended ("MiFID II"); (ii) a customer within the meaning of Directive (EU) 2016/97, as amended, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in Regulation (EU) 2017/1129, as amended. Consequently no key information document required by Regulation (EU) No 1286/2014, as amended (the "PRIIPs Regulation"), for offering or selling the securities or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the securities or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation. |

---

October 2015 Page 19

------

---

| |
|:---|
| ![](image1.gif)  |
| $3,145,000 Partial Principal at Risk Securities Based on the Value of the S&P 500<sup>®</sup> Index due June 4, 2031 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; **Prohibition** **of sales to United Kingdom retail investors:** | &nbsp;&nbsp;&nbsp; The only categories of person in the United Kingdom to whom this document may be distributed are those persons who (i) have professional experience in matters relating to investments falling within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order")), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000 ("FSMA")) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons in (i)-(iii) above together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. This document may only be provided to persons in the United Kingdom in circumstances where section 21(1) of FSMA does not apply to BNS. The securities are not being offered to "retail investors" within the meaning of the Packaged Retail and Insurance-based Investment Products Regulations 2017 and accordingly no Key Information Document has been produced under these regulations. |
| &nbsp;&nbsp; **Validity of the securities:**  | &nbsp;&nbsp;&nbsp; In the opinion of Fried, Frank, Harris, Shriver & Jacobson LLP, as special counsel to BNS, when the securities offered by this pricing supplement have been executed and issued by BNS and authenticated by the trustee pursuant to the indenture and delivered, paid for and sold as contemplated herein, the securities will be valid and binding obligations of BNS, enforceable against BNS in accordance with their terms, subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium, receivership or other laws relating to or affecting creditors' rights generally, and to general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity). This opinion is given as of the date hereof and is limited to the laws of the State of New York. Insofar as this opinion involves matters governed by Canadian law, Fried, Frank, Harris, Shriver & Jacobson LLP has assumed, without independent inquiry or investigation, the validity of the matters opined on by Osler, Hoskin & Harcourt LLP, Canadian legal counsel for BNS, in its opinion expressed below. In addition, this opinion is subject to customary assumptions about the trustee's authorization, execution and delivery of the indenture and, with respect to the securities, authentication of the securities and the genuineness of signatures and certain factual matters, all as stated in the opinion of Fried, Frank, Harris, Shriver & Jacobson LLP dated October 9, 2024 filed with the SEC as Exhibit 5.3 to the Registration Statement on Form F-3 on October 9, 2024.<br> In the opinion of Osler, Hoskin & Harcourt LLP, the issue and sale of the securities has been duly authorized by all necessary corporate action of BNS in conformity with the Indenture, and when the securities have been duly executed, authenticated and issued in accordance with the Indenture, and delivered against payment therefor, the securities will be validly issued and, to the extent validity of the securities is a matter governed by the laws of the Province of Ontario or the federal laws of Canada applicable therein, will be valid obligations of BNS, subject to the following limitations (i) the enforceability of the Indenture may be limited by the Canada Deposit Insurance Corporation Act (Canada), the Winding-up and Restructuring Act (Canada) and bankruptcy, insolvency, reorganization, receivership, preference, moratorium, arrangement or winding-up laws or other similar laws affecting the enforcement of creditors' rights generally; (ii) the enforceability of the Indenture may be limited by equitable principles, including the principle that equitable remedies such as specific performance and injunction may only be granted in the discretion of a court of competent jurisdiction; (iii) pursuant to the Currency Act (Canada) a judgment by a Canadian court must be awarded in Canadian currency and that such judgment may be based on a rate of exchange in existence on a day other than the day of payment; and (iv) the enforceability of the Indenture will be subject to the limitations contained in the Limitations Act, 2002 (Ontario), and such counsel expresses no opinion as to whether a court may find any provision of the Indenture to be unenforceable as an attempt to vary or exclude a limitation period under that Act. This opinion is given as of the date hereof and is limited to the laws of the Province of Ontario and the federal laws of Canada applicable therein. In addition, this opinion is subject to customary assumptions about the Trustees' authorization, execution and delivery of the Indenture and the genuineness of signatures and certain factual matters, all as stated in the letter of such counsel dated October 9, 2024, which has been filed as Exhibit 5.2 to BNS' Form F-3 filed with the SEC on October 9, 2024. |

---

October 2015 Page 20

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX Filing Fees

**Exhibit 107.1**

**CALCULATION OF FILING FEE TABLES**

**F-3**

**BANK OF NOVA SCOTIA**

Submission Type: 424B2

EX-FILING FEES

SEC File No. 333-282565

Final Prospectus: True

------

The pricing supplement to which this Exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price for such offering is $3,145,000.